I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| platelet | 10 studies | 62% ± 20% | |
| megakaryocyte | 6 studies | 68% ± 22% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| platelet | 10 studies | 62% ± 20% | |
| megakaryocyte | 6 studies | 68% ± 22% |
Insufficient scRNA-seq data for expression of MPIG6B at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 96% | 415.07 | 554 / 578 | 16% | 0.34 | 185 / 1155 |
| esophagus | 58% | 83.25 | 838 / 1445 | 43% | 1.05 | 78 / 183 |
| spleen | 99% | 519.05 | 239 / 241 | 0% | 0 | 0 / 0 |
| thymus | 51% | 53.11 | 335 / 653 | 42% | 0.83 | 253 / 605 |
| breast | 37% | 38.81 | 168 / 459 | 47% | 1.06 | 523 / 1118 |
| peripheral blood | 81% | 1114.07 | 748 / 929 | 0% | 0 | 0 / 0 |
| skin | 72% | 624.90 | 1304 / 1809 | 4% | 0.09 | 19 / 472 |
| ovary | 6% | 5.78 | 11 / 180 | 65% | 1.99 | 280 / 430 |
| uterus | 41% | 36.65 | 69 / 170 | 26% | 0.61 | 121 / 459 |
| bladder | 38% | 36.52 | 8 / 21 | 14% | 0.32 | 70 / 504 |
| intestine | 16% | 15.02 | 154 / 966 | 28% | 0.57 | 147 / 527 |
| stomach | 12% | 10.07 | 42 / 359 | 26% | 0.56 | 73 / 286 |
| adipose | 37% | 36.23 | 443 / 1204 | 0% | 0 | 0 / 0 |
| prostate | 26% | 22.49 | 64 / 245 | 4% | 0.08 | 20 / 502 |
| heart | 24% | 22.79 | 207 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 16% | 0.26 | 7 / 45 |
| brain | 2% | 2.71 | 66 / 2642 | 7% | 0.13 | 52 / 705 |
| blood vessel | 7% | 5.93 | 89 / 1335 | 0% | 0 | 0 / 0 |
| kidney | 3% | 3.67 | 3 / 89 | 2% | 0.04 | 22 / 901 |
| pancreas | 0% | 0 | 0 / 328 | 3% | 0.07 | 6 / 178 |
| liver | 2% | 1.59 | 4 / 226 | 1% | 0.02 | 4 / 406 |
| adrenal gland | 0% | 0 | 0 / 258 | 2% | 0.02 | 4 / 230 |
| muscle | 0% | 0.24 | 2 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0030218 | Biological process | erythrocyte differentiation |
| GO_0007229 | Biological process | integrin-mediated signaling pathway |
| GO_0030219 | Biological process | megakaryocyte differentiation |
| GO_0007596 | Biological process | blood coagulation |
| GO_0030220 | Biological process | platelet formation |
| GO_0009968 | Biological process | negative regulation of signal transduction |
| GO_0035855 | Biological process | megakaryocyte development |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0005794 | Cellular component | Golgi apparatus |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0008201 | Molecular function | heparin binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | MPIG6B |
| Protein name | Megakaryocyte and platelet inhibitory receptor G6b (Protein G6b) C6orf25 (Chromosome 6 open reading frame 25, isoform CRA_h) (cDNA FLJ35073 fis, clone PLACE6000630) C6orf25 protein (Megakaryocyte and platelet inhibitory receptor G6b) Megakaryocyte and platelet inhibitory receptor G6b C6orf25 (Megakaryocyte and platelet inhibitory receptor G6b) |
| Synonyms | C6orf25 hCG_43731 G6B-B G6B |
| Description | FUNCTION: Inhibitory receptor that acts as a critical regulator of hematopoietic lineage differentiation, megakaryocyte function and platelet production . Inhibits platelet aggregation and activation by agonists such as ADP and collagen-related peptide . This regulation of megakaryocate function as well as platelet production ann activation is done through the inhibition (via the 2 ITIM motifs) of the receptors CLEC1B and GP6:FcRgamma signaling . Appears to operate in a calcium-independent manner . .; FUNCTION: Isoform B, displayed in this entry, is the only isoform to contain both a transmembrane region and 2 immunoreceptor tyrosine-based inhibitor motifs (ITIMs) and, thus, the only one which probably has a role of inhibitory receptor. Isoform A may be the activating counterpart of isoform B. . |
| Accessions | O95866 ENST00000455185.6 [O95866-5] ENST00000433769.6 [O95866-5] ENST00000422012.6 [O95866-3] ENST00000436030.6 [O95866-1] ENST00000437153.6 [O95866-4] ENST00000442871.6 ENST00000449633.2 [O95866-5] ENST00000457884.6 [O95866-1] ENST00000435007.6 [O95866-3] ENST00000485548.5 ENST00000375810.8 [O95866-7] ENST00000447587.2 [O95866-1] A0A140T9V1 ENST00000445381.6 [O95866-3] ENST00000428302.6 [O95866-2] ENST00000649779.1 [O95866-1] ENST00000426729.6 [O95866-2] A0A0G2JJG8 ENST00000440063.6 [O95866-4] ENST00000441161.2 ENST00000438769.6 ENST00000415728.2 [O95866-1] A0A140T9L8 ENST00000431888.6 [O95866-5] ENST00000383410.4 [O95866-5] ENST00000383411.8 [O95866-3] ENST00000417610.2 [O95866-4] ENST00000480039.5 ENST00000415984.6 [O95866-5] ENST00000411608.6 [O95866-4] ENST00000375804.6 [O95866-4] ENST00000444404.6 [O95866-2] ENST00000383412.8 [O95866-2] B7ZLJ5 ENST00000375805.6 [O95866-3] B0V023 F8WDG3 ENST00000457450.6 [O95866-3] ENST00000375814.7 [O95866-5] ENST00000400071.7 [O95866-1] ENST00000400067.7 [O95866-4] ENST00000451549.6 [O95866-2] ENST00000425998.6 [O95866-4] ENST00000375809.7 [O95866-2] |
